Claritas Pharmaceuticals, Inc. Stock

CLAZF

CA1806342061

Biotechnology & Medical Research

Market Closed - OTC Markets 12:16:04 2026-02-27 pm EST			5-day change	1st Jan Change
0.000001 ^USD	-.--%		-.--%	-

Valuation: Claritas Pharmaceuticals, Inc.

Market Cap	5.37M 3.86M 3.34M 3.14M 2.85M 370M 5.45M 36.84M 14.44M 185M 14.51M 14.19M 617M	P/E 2019	-0.74x	P/E 2020	0.13x
Enterprise Value	6.29M 4.53M 3.91M 3.68M 3.34M 434M 6.38M 43.15M 16.91M 217M 17M 16.63M 723M	EV / Sales 2019	-	EV / Sales 2020	-
Free-Float	99.74%	Yield 2019 *	-	Yield 2020	-

* Estimated data More valuation ratios

Chart: Claritas Pharmaceuticals, Inc.

Dynamic Chart

Managers and Directors: Claritas Pharmaceuticals, Inc.

Manager	Title	Age	Since
Robert Farrell CEO	Chief Executive Officer	76	2017-06-20
Victoria Rudman DFI	Director of Finance/CFO	58	2018-06-28

Director	Title	Age	Since
Robert Farrell CHM	Chairman	76	2021-03-17

More insiders

Other Biotechnology & Medical Research

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
CLARITAS PHARMACEUTICALS, INC.	-.--%	-.--%	-	-	37
LONZA GROUP AG	-0.11%	-1.67%	+1.80%	+19.90%	48.63B
REVOLUTION MEDICINES, INC.	+1.89%	+5.08%	+492.59%	+629.24%	46.3B
BEONE MEDICINES AG	+1.83%	+2.75%	+15.61%	+91.22%	41.97B
IQVIA HOLDINGS INC.	-0.50%	-1.56%	+24.67%	+12.17%	39.51B
CELLTRION, INC.	-2.74%	-7.13%	+18.72%	+49.04%	31.75B
MEDPACE HOLDINGS, INC.	-1.14%	-2.51%	+27.52%	+136.42%	16.48B
ASCENDIS PHARMA A/S	+0.59%	-2.25%	-	-	16.34B
EUROFINS SCIENTIFIC SE	-0.03%	-0.34%	+3.45%	+29.14%	14B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-2.60%	-1.00%	+77.85%	+40.37%	13.33B
Average	-0.33%	-0.80%	+82.78%	+125.94%	26.83B
Weighted average by Cap.	+0.01%	-0.35%	+105.80%	+155.42%

See all sector performances

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Companyâ€™s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

Employees

Sector

Biotechnology & Medical Research

More about the company

Stock Market
Stocks
CLAZF Stock

All transcripts on over 9000 companies, on the day they post their earnings!

Unlock them now!

Current year	0		0
1 year	0		0
3 years	0		0
5 years	0		0.4
10 years	0		15.31

Date	Insider	Type	Quantity	% Market Cap.
10/11/21	Andrew Salzman	Buy	118,000	0.3332%
10/11/21	Andrew Salzman	Buy	152,500	0.4307%
10/11/21	Andrew Salzman	Buy	24,500	0.0692%

	2019	2020
Net sales	-	-
Net income	-21.21M -15.27M -13.19M -12.41M -11.28M -1.46B -21.52M -146M -57.04M -732M -57.33M -56.09M -2.44B	4.21M 3.03M 2.62M 2.46M 2.24M 290M 4.27M 28.89M 11.32M 145M 11.38M 11.13M 484M
Net Debt	704K 507K 438K 412K 374K 48.56M 714K 4.83M 1.89M 24.29M 1.9M 1.86M 80.89M	920K 662K 572K 538K 489K 63.46M 933K 6.31M 2.47M 31.74M 2.49M 2.43M 106M

Claritas Pharmaceuticals, Inc. Stock

Stocks

CLAZF

CA1806342061

Biotechnology & Medical Research

Valuation: Claritas Pharmaceuticals, Inc.

Chart: Claritas Pharmaceuticals, Inc.

Course Extremes

Managers and Directors: Claritas Pharmaceuticals, Inc.

Latest insider transactions

Other Biotechnology & Medical Research

Financials

Company Profile